Abstract:1114 Objectives Octreotide and its derivatives have been widely used for SSTR positive tumors therapy, however, they only have high affinity of SSTR 2 among the five somatostatin receptors[1, 2]. Recently, Pasireotide was reported to have a better binding affinity of SSTR 1, 3, 5 and similar affinity of SSTR 2 compared with Octreotide[3, 4].The purpose of this work was to develop a new somatostatin analogue Pasireotide labeled by 177Lu to explore the possibility of its usage as a diagnostic and therapeutic radiopharmaceutical for neuroendocrine tumors and peptide receptor radionuclide therapy (PRRNT). Methods Cyclic peptide amide DOTA-Pasireotide was synthesized and radiolabeled with 177Lu to yield 177Lu-DOTA-Pasireotide (Figure.1). The precursor DOTA-Pasireotide was labeled with 177Lu in sodium acetate buffer (pH 4.0) by heating at 100 °C for 15 min and the products were determained by Radio-ITLC and radio-HPLC. In vitro stability experiments was taken in 5% human serum albumin, NaAc (pH 5.5) and PBS (pH 7.4) at room temperature (25 °C) for about 120 hours of incubation. After 12.95 MBq of 177Lu-DOTA-Pasireotide was injected intravenously to BALB/c nude mice bearing human HT29 colon tumors via tail vein, the SPECT/CT images were taken 2 h, 4 h, 8 h after radiotracer injection. Results 177Lu was radiolabeled with DOTA-Pasireotide in 98% radiochemical yield as determined by radio-TLC and radio-HPLC. In vitro stability experiments showed in 120 hours 177Lu-DOTA-Pasireotide was stable in 5% human serum albumin, NaAc (pH 5.5) and PBS (pH 7.4). In vivo, the HT29 cell xenograft tumors uptake of 177Lu-DOTA-Pasireotide were clearly visualized by 8 h postinjection. Conclusions We described the Radio-synthesis and characterization of 177Lu-DOTA-Pasireotide. It’s found to have high labeling efficiencies, short labeling time and high tumor cell uptakes. In brief, 177Lu-DOTA-Pasireotide may be useful both for cancer diagnostic and therapeutic applications. Research Support Supported by grant #81172083, grant #81371592 and grant #81401467 from the National Natural Science Foundation of China and by #7132040 from the Beijing Municipal Natural Science Foundation of China.

Preparation Of~(188)re-Lanreotide As a Potential Tumor Therapeutic Agent

Preparation of (188re) Re-AEDP and Its Biodistribution Studies.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Preparation and preliminary biological evaluation of Lu-177 labeled somatostatin analogue DOTA-Pasireotide.

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

Introduction of Re-188 to enhance the inhibiting effect of Bevacizumab for Non-small-cell Lung Cancer

Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach

Evaluating the Potential of (188)Re-Ecd/lipiodol As a Therapeutic Radiopharmaceutical by Intratumoral Injection for Hepatoma Treatment.

In vitro structure-activity relationship of Re-cyclized octreotide analogues

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

Preparation and Micropet Imaging of Somatostatin Receptor Antagonist 68 Ga-NOTA-JR11

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma

Preparation of 90Y-Labeled Different Cyclic RGD Peptides and Evaluation in Nude Mice Bearing Human Glioma Xenografts

Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.

Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy

Evaluation of 188Re-Mag2-rgd-bombesin for Potential Prostate Cancer Therapy

Design, Synthesis and Iodination of an Arg‐Arg‐Leu Peptide for Potential Use As an Imaging Agent for Human Prostate Carcinoma

Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging

Comparison study of two18F labeling methods of peptides